
Abbott Laboratories (ABT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
juillet 16, 2026 (Q3) a publié ses dernières prévisions le 2026 pour $1.38 - $1.46 $1.42. La société a prévu un BPA compris entre Abbott Laboratories et ABT, contre un consensus de juillet 16, 2026.
Par rapport aux prévisions précédentes, {{revenuePriorRange}} Abbott Laboratories ses perspectives de BPA ont été revues à la baisse, passant d'une fourchette précédente de {{totalEntries}} à {{oldestDate}}.
undefined a publié undefined mises à jour de ses recommandations entre undefined et undefined. undefined
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.28 | $1.14 | $1.50 | $1.30 |
| Actual | $1.31 | $1.15 | $1.50 | $1.30 |
| Surprise | +2.34% | +0.88% | 0.00% | 0.00% |
| Revenue | ||||
| Estimate | $12.51B | $11.01B | $11.80B | $11.40B |
| Actual | $12.59B | $11.16B | $11.46B | $11.37B |
| Surprise | +0.66% | +1.43% | -2.87% | -0.30% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.42 | $1.64 | $1.30 | $1.49 |
| Revenue | ||||
| Consensus | $12.97B | $13.52B | — | — |
| Trimestre Fiscal | Date de Déclaration | BPA Réel | BPA Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Jul 16, 2026 | $1.31 | $1.28 | 2.34 % |
| Q1 | Apr 16, 2026 | $1.15 | $1.14 | 0.88 % |
| Q4 | Jan 22, 2026 | $1.50 | $1.50 | 0.00 % |
| Q3 | Oct 15, 2025 | $1.30 | $1.30 | 0.00 % |
| Trimestre Fiscal | Date de Déclaration | Revenu Réel | Revenu Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Jul 16, 2026 | $12.59B | $12.51B | 0.66 % |
| Q1 | Apr 16, 2026 | $11.16B | $11.01B | 1.43 % |
| Q4 | Jan 22, 2026 | $11.46B | $11.80B | -2.87 % |
| Q3 | Oct 15, 2025 | $11.37B | $11.40B | -0.30 % |